Hims & Hers Health Inc. Forecast, price target & analysts
Hims & Hers Health Inc. Target price 2025 - Analyst rating & recommendation
Hims & Hers Health Inc. Classifications & Recommendation:
Hims & Hers Health Inc. Price Target
| Target Price | $35.93 |
| Price | $49.28 |
| Deviation |
27.08%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Hims & Hers Health Inc. 2026 .
The average Hims & Hers Health Inc. target price is $35.93.
This is
27.08%
register free of charge
$85.00
72.48%
register free of charge
$21.00
57.39%
register free of charge
|
|
| A rating was issued by 16 analysts: 7 Analysts recommend Hims & Hers Health Inc. to buy, 7 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hims & Hers Health Inc. stock has an average upside potential 2026 of
27.08%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.87 | 1.47 |
| 65.49% | 68.15% | |
| EBITDA Margin | -2.75% | 12.09% |
| 76.28% | 540.19% | |
| Net Margin | -2.75% | 7.93% |
| 79.23% | 388.60% |
15 Analysts have issued a sales forecast Hims & Hers Health Inc. 2024 . The average Hims & Hers Health Inc. sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Hims & Hers Health Inc. EBITDA forecast 2024. The average Hims & Hers Health Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Hims & Hers Health Inc. Analysts have issued a net profit forecast 2024. The average Hims & Hers Health Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.11 | 0.53 |
| 65.63% | 581.82% | |
| P/E | 92.27 | |
| EV/Sales | 7.18 |
14 Analysts have issued a Hims & Hers Health Inc. forecast for earnings per share. The average Hims & Hers Health Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Hims & Hers Health Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Hims & Hers Health Inc....
Current Hims & Hers Health Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities | Underperform ➜ Underperform | Unchanged | Feb 20 2025 |
| Canaccord Genuity | Buy ➜ Buy | Unchanged | Feb 19 2025 |
| Morgan Stanley | Overweight ➜ Equal-Weight | Downgrade | Feb 18 2025 |
| Citigroup | Neutral ➜ Sell | Downgrade | Jan 10 2025 |
| BTIG | ➜ Buy | Initiated | Jan 07 2025 |
| Needham | Buy ➜ Buy | Unchanged | Jan 06 2025 |
| Piper Sandler | Neutral ➜ Neutral | Unchanged | Jan 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
B of A Securities: Underperform ➜ Underperform
|
Feb 20 2025 |
|
Unchanged
Canaccord Genuity: Buy ➜ Buy
|
Feb 19 2025 |
|
Downgrade
Morgan Stanley: Overweight ➜ Equal-Weight
|
Feb 18 2025 |
|
Downgrade
Citigroup: Neutral ➜ Sell
|
Jan 10 2025 |
|
Initiated
BTIG: ➜ Buy
|
Jan 07 2025 |
|
Unchanged
Needham: Buy ➜ Buy
|
Jan 06 2025 |
|
Unchanged
Piper Sandler: Neutral ➜ Neutral
|
Jan 06 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
